Controlling cancer by restricting arginine availability--arginine-catabolizing enzymes as anticancer agents.
Wheatley
Denys N
DN
BioMedES, Aberdeen, UK. wheatley@abdn.ac.uk
D000818:Animals; D000970:Antineoplastic Agents / Q000378:metabolism* / Q000627:therapeutic use*; D001119:Arginase / Q000378:metabolism* / Q000494:pharmacology / Q000627:therapeutic use*; D001120:Arginine / Q000037:antagonists & inhibitors / Q000172:deficiency / Q000378:metabolism*; D002262:Carboxy-Lyases / Q000378:metabolism / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology* / Q000378:metabolism
D000970:Antineoplastic Agents; D001120:Arginine; D001119:Arginase; D002262:Carboxy-Lyases; C019722:arginine decarboxylase